Genetic mutation predicts pancreatic cancer metastasis and survival
A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0 ...
Pharmabiz20h
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...
Zydus Lifesciences shares rally 3% after FDA approval for prostate cancer drug
Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...
Zydus Life receives USFDA approval for manufacturing Apalutamide tablets, 60 mg
Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Apalutamide tablets, 60 mg.
MedPage Today on MSN22h
End of the Road for Immune Checkpoint Inhibitors in Prostate Cancer?
Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...
Zydus Lifesciences jumps 8% as USFDA approves Apalutamide tablets
Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...